Peptide Atlas · Other substance

Thymostimulin (TP-1)

In a double-blind, placebo-controlled trial in 29 patients with severe atopic eczema, ten weeks of thymostimulin improved clinical scores at three months, but the difference did not last and immunological measures did not change.

emerging

provisional
2 citations
0 discussions
0 followers
TP-1
calf thymus extract TP-1
thymostimulin

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

emerging — human data exists, and it is thin or contested

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

Evidence, kept apart

The Atlas never mixes evidence types into one blob. Each claim below carries the tier it actually sits in; an unresolved citation is shown and does not move the page.

Evidence map for Thymostimulin (TP-1). Tier reflects study design, not enthusiasm.
Claim	Tier	Source
Thymostimulin in severe atopic eczema: transient benefit (RCT, n=29)	emerging	pmid 1835403
Thymostimulin increased survival of tumour-bearing mice	preclinical	pmid 7248976

Unanswered questions

No open questions on file. Either everything about this molecule is known, or nobody has admitted what is not.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.